Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.

Cardio Risk in RA: Not Just Heart Attacks and Strokes

Rates of aortic stenosis were almost 50% higher in U.S. veterans with rheumatoid arthritis (RA) relative to other individuals in the Veterans Affairs health system,

August 2, 2023

Protective genetic variant shields Black Americans from kidney disease risk

Many Black Americans who are thought to have a high risk of developing kidney disease possess a protective genetic variant that nullifies the extra risk,

December 13, 2023

ImmunityBio inks $320m deal to advance bladder cancer drug and boost pipeline – Pharmaceutical Technology

Share this article The latest investment brings ImmunityBio’s total financing from 2023 to $850m. Credits: jack8/Shutterstock.com ImmunityBio has started the year off strong by announcing

January 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.